ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed
Rebecca S. Slack Tidwell
Matched on ORCID iD 0000-0003-3041-8582; OpenAlex author ID A5026202651. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 30
2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 2 papers
Papers 4
- Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-control… Co-author DOI 10.1016/s1470-2045(23)00478-3↗
- Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000005184↗
- Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer. Co-author DOI 10.1200/po.21.00212↗
- Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic… Co-author DOI 10.1016/j.ijrobp.2020.09.022↗
Closest collaborators
The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ying Yuan · 3 shared papers, 2020–2023 · strength 0.43
- Paper Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer. DOI 10.1200/po.21.00212↗
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Shubham Pant · 3 shared papers, 2020–2023 · strength 0.36
- Paper Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic … DOI 10.1097/sla.0000000000005184↗
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Ching-Wei David Tzeng · 3 shared papers, 2020–2023 · strength 0.36
- Paper Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic … DOI 10.1097/sla.0000000000005184↗
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Matthew H. G. Katz · 2 shared papers, 2023 · strength 0.27
- Paper Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic … DOI 10.1097/sla.0000000000005184↗
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Robert A. Wolff · 2 shared papers, 2023 · strength 0.27
- Paper Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic … DOI 10.1097/sla.0000000000005184↗
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Ethan Bernard Ludmir · 2 shared papers, 2023 · strength 0.27
- Paper Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic … DOI 10.1097/sla.0000000000005184↗
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Eugene Jon Koay · 2 shared papers, 2023 · strength 0.27
- Paper Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic … DOI 10.1097/sla.0000000000005184↗
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Brian G. Czito · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Lauren Elizabeth Colbert · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Jessica M. Frakes · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Todd Anthony Aguilera · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Manisha Palta · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Joseph M. Herman · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Shalini Moningi · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Sarah E. Hoffe · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Cullen M. Taniguchi · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Manoop S. Bhutani · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Michael James Overman · 1 shared paper, 2023 · strength 0.15
- Timothy Eric Newhook · 1 shared paper, 2023 · strength 0.15
- Naruhiko Ikoma · 1 shared paper, 2023 · strength 0.15
- Laura R. Prakash · 1 shared paper, 2023 · strength 0.15
- Timothy J. Vreeland · 1 shared paper, 2023 · strength 0.15
- Michael P. Kim · 1 shared paper, 2023 · strength 0.15
- Brandon George Smaglo · 1 shared paper, 2023 · strength 0.15
- Jeffrey E. Lee · 1 shared paper, 2023 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.